TASK Clinical Research Centre
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diacon, Andreas
Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting
3b
500000
RoW
Booster vaccine
Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine
SARS CoV 2 Infection
01/22
06/23
NCT05896930: Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

Completed
2
134
RoW
Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV, Ertapenem 1g IV, Amoxicillin/CA twice daily, Rifampicin 35 mg/kg, Meropenem 6g IV over 60 minutes, Rifafour e-275, Meropenem 4g IV, Amoxicillin/CA once daily
TASK Applied Science
Pulmonary Tuberculosis
01/21
01/21
NCT04621825: Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam

Completed
N/A
187
RoW
ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.
Advanced Medical Solutions Ltd., Imarc Research, Inc.
Wound
05/24
07/24
Jager, Veronique R de
NCT05388448: EBA, Safety and Tolerability of Sanfetrinem Cilexetil

Recruiting
2
105
RoW
Sanfetrinem Cilexetil, Compound number GV118819, Amoxicillin/clavulanic acid, Amoclan, Rifampicin, Rifadin
TASK Applied Science, GlaxoSmithKline, European and Developing Countries Clinical Trials Partnership (EDCTP)
Tuberculosis, Pulmonary
09/23
12/23
NCT05382312: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Recruiting
2
128
RoW
GSK3036656, Bedaquiline, Delamanid, RIFAFOUR e-275, BTZ-043
GlaxoSmithKline, Click-TB Consortium
Tuberculosis
11/24
11/24
BETO, NCT05473195: A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

Recruiting
2
105
RoW
BVL-GSK098 9mg, Ethionamide 125 and 250mg, Ethionamide 250mg, Ethionamide 250 mg, Isoniazid 300 MG
TASK Applied Science
Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
10/23
10/23
NCT06041919: Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Active, not recruiting
2
75
RoW
RESP301, HRZE
Thirty Respiratory Limited
Rifampicin Susceptible Pulmonary Tuberculosis
04/25
07/25
Davids, Lee-Ann
NCT06041919: Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis

Active, not recruiting
2
75
RoW
RESP301, HRZE
Thirty Respiratory Limited
Rifampicin Susceptible Pulmonary Tuberculosis
04/25
07/25
NCT05807399: PanACEA - STEP2C -01

Recruiting
2
270
RoW
BTZ-043, Rifampicin, Isoniazid, Pyrazinamide, Moxifloxacin
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
02/25
02/25

Download Options